Search results
Showing 1 to 6 of 6 results for donanemab
In development [GID-TA11221] Expected publication date: 23 July 2025
In development [GID-TA11379] Expected publication date: TBC
Our forward view highlights the areas we will prioritise in the coming year.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.